NCT07847281
A Study of AK157D1 for Injection in Advanced Solid Tumors
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 2 versions: 2 with changes below.
- Notable Recruitment opened
- Start date changed from estimate of Sep 21, 2026 to Sep 30, 2026
- Site details revised at 3 of 3 sites
- Study First Submitted
- Notable: the plan changed
Endpoints
Primary
Number of participants with dose limiting toxicities (DLTs)
Timeframe: During the first 3 weeks of treatment.
Number of participants with adverse events (AEs)
Timeframe: From the time of signing informed consent form through 30 days(for AEs) or 90 days(for SAEs) after the last dose of study drug.
Secondary (13)
Area under curve (AUC)
Maximum Concentration (Cmax)
Peak Time (Tmax)
The terminal elimination half-life (t1/2)
Clearance (CL)
Show 8 moreShow less
Volume of distribution (V)
Anti-drug antibodies (ADA)
Objective Response Rate (ORR) assessed by investigator per RECIST v1.1
Disease Control Rate (DCR) assessed per RECIST v1.1
Duration of response (DoR) assessed by the investigator per RECIST v1.1
Time to response (TTR) assessed by the investigator per RECIST v1.1
Progression Free Survival (PFS) assessed by investigator per RECIST v1.1
Overall survival (OS)
Arms and interventions
AK157D1 for injectionExperimental
AK157D1 for injection will be administered in prespecified dose levels
Drugs: AK157D1 for injection
Sites
3 sites in 1 country